Sat.Aug 01, 2020 - Fri.Aug 07, 2020

article thumbnail

First oral drug for spinal muscular atrophy approved by FDA

Bio Pharma Dive

Approval of Evrysdi, from Roche and PTC Therapeutics, adds a third option for treating the neuromuscular disease, joining Spinraza and Zolgensma.

Drugs 353
article thumbnail

COVID-19 and obesity is a lethal mix

World of DTC Marketing

QUICK READ : Obesity is associated with a higher risk of developing severe symptoms and complications of coronavirus disease, independent of other illnesses, such as cardiovascular disease. So why haven’t we acted? Data seems to suggest that people with obesity are more likely to become severely ill due to COVID-19, the disease caused by the novel coronavirus.

Doctor 295
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Developing Drug Products with the Label’s Commercial Value in Mind

Camargo

Whether you plan to out-license or commercialize your product, getting the label right matters. When. The post Developing Drug Products with the Label’s Commercial Value in Mind appeared first on Camargo.

article thumbnail

Researchers says hydroxychloroquine could still prevent COVID-19

Pharma Times

Scientists from the University of Oxford say the drug is being ‘discarded prematurely’

Scientist 170
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

With first results, Novavax takes step forward in coronavirus vaccine race

Bio Pharma Dive

Early-stage results appear to show that Novavax's shot passed its first meaningful test, helping the Maryland biotech keep pace with larger competitors.

article thumbnail

On the pharma ecosystem

World of DTC Marketing

QUICK READ: There are a lot of patient-centered, hard-working people within the pharma industry. The problem is that there are way too many senior managers whose only goal is to remain relevant within the organization even if it means patients suffer. Trade magazine awards don’t mean anything if one company makes a bad decision that stains our industry.

More Trending

article thumbnail

UK increases COVID-19 vaccine manufacturing capacity

Pharma Times

New deal with Wockhardt boosts capacity at the crucial 'fill and finish' stage

article thumbnail

Lilly to test COVID-19 antibody drug in unorthodox nursing home study

Bio Pharma Dive

Seeking fast answers in a pandemic, Lilly will use mobile RVs to set up infusion clinics at assisted living facilities, which have become COVID-19 hot spots.

Nurses 341
article thumbnail

Will people line up for a COVID-19 vaccine?

World of DTC Marketing

QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. Personally I would want to know as much as I can before I ask for the vaccine but I also know that greed can make people do stupid things and there is a lot of money at stake here. The rush to develop a COVID-19 vaccine is well underway because there are billions of dollars in profits at stake.

article thumbnail

Top 12 Biotech Companies Hiring Now

BioSpace

According to BioSpace research, 69% of biotech professionals feel they are on the verge of job burnout. Do you fall into that 69%? Is it time for a new job? Check out the top companies who are looking for candidates like you right now!

Research 142
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

AstraZeneca forges licensing agreement with Redx Pharma

Pharma Times

AZ will pay $17m in early milestone payments for the UK biotech’s fibrotic asset

Licensing 134
article thumbnail

Big pharma alliance recruits first patients for unusual COVID-19 study

Bio Pharma Dive

The trial is testing whether drugs from Amgen, Takeda and AbbVie can combat the life-threatening immune overreaction some COVID-19 patients experience.

Trials 340
article thumbnail

Health Experts to F.D.A.: Make Your Vaccine Deliberations Public

NY Times

A letter signed by nearly 400 health experts asked the agency to use its vaccine advisory panel when reviewing data on coronavirus trials.

article thumbnail

Restoring Cellular Power Outages: A New Drug to Treat Mitochondrial Diseases

BioSpace

A small biotech company is aiming to recharge tired cells, giving mitochondrial disease patients new hope of a disease-specific treatment.

Drugs 137
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Pharma’s reputation has climbed during COVID-19 pandemic, study finds

Pharma Times

Roche, AstraZeneca, Novo Nordisk and Sanofi all climbed index rankings

132
132
article thumbnail

Editas, AbbVie rework gene editing deal as pioneering CRISPR trial resumes

Bio Pharma Dive

Development of EDIT-101, the first CRISPR-based therapy to be used in a company-led trial to alter genes within a person's body, will now move forward under Editas' sole ownership.

article thumbnail

How does HTA for orphan drugs differ across Europe?

pharmaphorum

New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines across Europe. Rare diseases drugs have always faced challenges when it comes to HTA approvals, even as governments bring in more regulatory policies that make their path through assessment easier. Several factors make it difficult for HTA bodies often to assess orphan drugs, including a lack of robust trial data due to difficulties in finding patients, the absence of randomised controlled tri

Drugs 122
article thumbnail

With Court Win, BMS and Pfizer Stave Off Generic Challengers to Eliquis – For Now

BioSpace

Investors in Bristol Myers Squibb and Pfizer are singing a happy song this morning after a federal court upheld patent claims regarding Eliquis, which blocks generic rivals from carving out a share of the market for at least six years.

Marketing 135
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Cosentyx wins EU approval for first-line paediatric psoriasis

Pharma Times

Low-dose and high-dose Cosentyx is effective in rapidly improving skin symptoms and quality of life

130
130
article thumbnail

Moderna sets high price in early coronavirus vaccine supply deals

Bio Pharma Dive

Early preorders for small quantities of Moderna's shot set a price per dose of $32 to $37, although the biotech plans to charge less in larger agreements.

article thumbnail

CSafe, Cloudleaf partner on cold-chain tracking tech

Outsourcing Pharma

The firms are working to create a platform that gives the ability to monitor temperature-sensitive treatments, vaccines and other products.

article thumbnail

uniQure Begins First-in-Human Gene Therapy Trials for Huntington’s Disease

BioSpace

In June, it dosed its first two patients using a novel therapeutic, AMT-130, delivered directly to the brain. Initial readouts are expected in a year’s time.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Oxford Biomedica and Beam Therapeutics sign CAR-T deal

Pharma Times

Agreement will utilise Oxford Biomedica's LentiVector platform

128
128
article thumbnail

FDA agrees to review Biogen's Alzheimer's drug

Bio Pharma Dive

The agency's decision kicks off a historic and dramatic regulatory review, as significant lingering questions surround aducanumab's approval chances.

Drugs 336
article thumbnail

Pfizer signs deal with Gilead to manufacture COVID-19 antiviral remdesivir

pharmaphorum

Pfizer has signed a multi-year agreement with Gilead to manufacture and supply the COVID-19 antiviral remdesivir, which is also being tested in combination with other drugs in an effort to fight the pandemic. Under the terms of the agreement Pfizer will become one of several external partners who manufacture the investigational treatment for the disease.

article thumbnail

Octapharma Uses IVIG as Potential Treatment for COVID-19

BioSpace

Intravenous immunoglobulin (IVIG) could be a key to combating seriously ill COVID-19 patients who have been hospitalized due to complications from the disease, and Octapharma AG aims to find out as it assesses the plasma-based treatment in a Phase III study.

121
121
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Roche’s tumour-agnostic therapy Rozlytrek approved in EU

Pharma Times

Therapy has been approved to treat advanced NTRK fusion-positive solid tumours

128
128
article thumbnail

Novartis says CAR-T cancer therapy works in second lymphoma type

Bio Pharma Dive

Early results from a trial testing Kymriah in follicular lymphoma were reportedly positive, supporting the pharma's plans to ask for another approval.

Trials 310
article thumbnail

Combining the Powers of Single Cell Sequencing and AI in Understanding Disease Biology and Drug Development

XTalks

Single cell sequencing has revolutionized the study of biological tissues and systems at the cellular and molecular level. Recent advances in the technology have allowed for the interrogation of distinct subsets of cell populations within tissues, and associated molecular markers that may function as important disease drivers. The use of single cell sequencing in profiling bulk, heterogeneous tissues at the single cell level can help in the identification of dominant, unique and rare cell subtyp

article thumbnail

Fearing Brexit chaos, UK asks pharma to build six-week drug stockpile

pharmaphorum

The UK government has asked pharma companies to build a six-week stockpile of drugs and find alternative shipping routes to the congested Dover-Calais crossing as the country heads for Brexit at the end of the year. In a letter , Steve Oldfield, chief commercial officer at the Department of Health and Social Care, said the government is focused on preventing potential disruption to any categories of medical supplies.

Drugs 111
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.